Table 3 Completed clinical trials based on monotherapy with anti-PD-1/PD-L1 therapy for renal cell carcinoma (RCC) registered in ClinicalTrials.gov (June 2022)

Nivolumab

2

730

N/A

3 mg/kg

France

NCT03013335

Nivolumab

1

17

N/A

3 mg/kg

USA

NCT02575222

Nivolumab

4

197

N/A

3 mg/kg

USA

NCT02596035

Nivolumab

3

1068

Randomized

3 mg/kg

International

NCT01668784

Nivolumab

2

68

Randomized

0.3–10 mg/kg

International

NCT01354431

Nivolumab

1

395

Non-Randomized

0.1–10 mg/kg

USA

NCT00730639

Nivolumab

1

39

Non-Randomized

0.3–10 mg/kg

USA

NCT00441337

Pembrolizumab

2

275

Non-Randomized

200 mg

UK

NCT02853344